Latest & greatest articles for simvastatin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on simvastatin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on simvastatin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for simvastatin

41. Simvastatin was cost effective across a broad range of risk and age groups

Simvastatin was cost effective across a broad range of risk and age groups Simvastatin was cost effective across a broad range of risk and age groups | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Simvastatin was cost effective across a broad range of risk and age groups Article Text Economics Simvastatin was cost effective across a broad range of risk and age groups Statistics from Altmetric.com No Altmetric data available for this article. Request permissions If you wish to reuse any or all of this article please use the link below which will take you

Evidence-Based Medicine (Requires free registration)2008

42. Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective

Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective Costa-Scharplatz M, Ramanathan K, Frial T, Beamer B, Gandhi S Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to examine the cost-effectiveness of rosuvastatin in comparison with atorvastatin, simvastatin, and pravastatin for managing lipid parameters in patients with hypercholesterolaemia. The authors

NHS Economic Evaluation Database.2008

43. Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.

Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial. 18632543 2008 07 17 2008 07 23 2016 11 22 1538-3598 300 3 2008 Jul 16 JAMA JAMA Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial. 287-94 10.1001/jama.300.3.287 Neurofibromatosis type 1 (NF1) is among the most common genetic disorders that cause learning disabilities. Recently, it was shown that statin (...) -mediated inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase restores the cognitive deficits in an NF1 mouse model. To determine the effect of simvastatin on neuropsychological, neurophysiological, and neuroradiological outcome measures in children with NF1. Sixty-two of 114 eligible children (54%) with NF1 participated in a randomized, double-blind, placebo-controlled trial conducted between January 20, 2006, and February 8, 2007, at an NF1 referral center at a Dutch university hospital

JAMA2008 Full Text: Link to full Text with Trip Pro

44. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.

Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. 18765433 2008 09 25 2008 09 30 2015 11 19 1533-4406 359 13 2008 Sep 25 The New England journal of medicine N. Engl. J. Med. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. 1343-56 10.1056/NEJMoa0804602 Hyperlipidemia has been suggested as a risk factor for stenosis of the aortic valve, but lipid-lowering studies have had conflicting results. We conducted a randomized, double-blind trial (...) involving 1873 patients with mild-to-moderate, asymptomatic aortic stenosis. The patients received either 40 mg of simvastatin plus 10 mg of ezetimibe or placebo daily. The primary outcome was a composite of major cardiovascular events, including death from cardiovascular causes, aortic-valve replacement, nonfatal myocardial infarction, hospitalization for unstable angina pectoris, heart failure, coronary-artery bypass grafting, percutaneous coronary intervention, and nonhemorrhagic stroke. Secondary

NEJM2008

45. Simvastatin with or without ezetimibe in familial hypercholesterolemia.

Simvastatin with or without ezetimibe in familial hypercholesterolemia. 18376000 2008 04 03 2008 04 10 2016 11 24 1533-4406 358 14 2008 Apr 03 The New England journal of medicine N. Engl. J. Med. Simvastatin with or without ezetimibe in familial hypercholesterolemia. 1431-43 10.1056/NEJMoa0800742 Ezetimibe, a cholesterol-absorption inhibitor, reduces levels of low-density lipoprotein (LDL) cholesterol when added to statin treatment. However, the effect of ezetimibe on the progression (...) of atherosclerosis remains unknown. We conducted a double-blind, randomized, 24-month trial comparing the effects of daily therapy with 80 mg of simvastatin either with placebo or with 10 mg of ezetimibe in 720 patients with familial hypercholesterolemia. Patients underwent B-mode ultrasonography to assess the intima-media thickness of the walls of the carotid and femoral arteries. The primary outcome measure was the change in the mean carotid-artery intima-media thickness, which was defined as the average

NEJM2008

46. Effect of coenzyme q10 supplementation on simvastatin-induced myalgia.

Effect of coenzyme q10 supplementation on simvastatin-induced myalgia. Myalgia is the most frequently reported adverse side effect associated with statin therapy and often necessitates reduction in dose, or the cessation of therapy, compromising cardiovascular risk management. One postulated mechanism for statin-related myalgia is mitochondrial dysfunction through the depletion of coenzyme Q(10), a key component of the mitochondrial electron transport chain. This pilot study evaluated (...) the effect of coenzyme Q(10) supplementation on statin tolerance and myalgia in patients with previous statin-related myalgia. Forty-four patients were randomized to coenzyme Q(10) (200 mg/day) or placebo for 12 weeks in combination with upward dose titration of simvastatin from 10 mg/day, doubling every 4 weeks if tolerated to a maximum of 40 mg/day. Patients experiencing significant myalgia reduced their statin dose or discontinued treatment. Myalgia was assessed using a visual analogue scale

EvidenceUpdates2007

47. A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin

A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin Rogers S L, Magliano D J, Levison D B, Webb K, Clarke P J, Grobler M P, Liew D CRD summary The authors concluded that atorvastatin appears more effective than (...) simvastatin in reducing total cholesterol, low-density lipoprotein cholesterol and triglycerides, with a dose equivalence of between 1:2 and 1:4. Simvastatin appears more effective than atorvastatin in increasing high-density lipoprotein cholesterol, with no indication of dose-equivalence. The review was generally well-conducted and these conclusions seem likely to be reliable. Authors' objectives To assess the relative potency of atorvastatin and simvastatin in altering serum lipid levels. Searching

DARE.2007

48. Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting

Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting Usher-Smith J (...) A, Ramsbottom T, Pearmain H, Kirby M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined switching the patients' medication from 10 or 20g atorvastatin to 20 or 40 mg simvastatin for the treatment of high cholesterol, and

NHS Economic Evaluation Database.2007

49. A model for assessing the cost-effectiveness of atorvastatin and simvastatin in achieving Canadian low-density lipoprotein cholesterol targets

A model for assessing the cost-effectiveness of atorvastatin and simvastatin in achieving Canadian low-density lipoprotein cholesterol targets A model for assessing the cost-effectiveness of atorvastatin and simvastatin in achieving Canadian low-density lipoprotein cholesterol targets A model for assessing the cost-effectiveness of atorvastatin and simvastatin in achieving Canadian low-density lipoprotein cholesterol targets Lachaine J, Merikle E, Tarride J E, Montpetit M, Rinfret S Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared the cost-effectiveness of two cholesterol-lowering pharmaceuticals, atorvastatin (10 to 80 mg/day) and generic simvastatin (10 to 80 mg/day). Statin medications treat

NHS Economic Evaluation Database.2007

50. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin

Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin Lindgren P, Graff J, Olsson A G, Pedersen T J, Jonsson B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study evaluated the long-term cost-effectiveness of two options for the secondary prevention of cardiovascular disease in patients, under 80 years old, who had experienced acute myocardial infarction. At a willingness-to-pay of 50,000 Euros per quality-adjusted life-year, atorvastatin was cost-effective compared with simvastatin in Denmark, Norway and Sweden, while in Finland

NHS Economic Evaluation Database.2007

51. Are statins created equal: evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention

Are statins created equal: evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention Are statins created equal: evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention Are statins created equal: evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention Zhou Z, Rahme E, Pilote L CRD summary This review assessed (...) the relative efficacy of pravastatin, simvastatin and atorvastatin. The authors concluded that the evidence suggests there is no statistically significant difference in long-term cardiovascular outcomes between standard doses of these statins. Statements on relative efficacy were based on indirect comparisons, thus the authors' cautious conclusion appears appropriate. Authors' objectives To assess the relative efficacy of pravastatin, simvastatin and atorvastatin. Searching MEDLINE and the Cochrane

DARE.2006

52. Cost-effectiveness of rosuvastatin, atorvastatin, simvastatin, pravastatin and fluvastatin for the primary prevention of CHD in the UK

Cost-effectiveness of rosuvastatin, atorvastatin, simvastatin, pravastatin and fluvastatin for the primary prevention of CHD in the UK Cost-effectiveness of rosuvastatin, atorvastatin, simvastatin, pravastatin and fluvastatin for the primary prevention of CHD in the UK Cost-effectiveness of rosuvastatin, atorvastatin, simvastatin, pravastatin and fluvastatin for the primary prevention of CHD in the UK Davies A, Hutton J, O'Donnell J, Kingslake S Record Status This is a critical abstract (...) rosuvastatin (ROS), atorvastatin (ATO), simvastatin (SIM), pravastatin (PRA) and fluvastatin (FLU). Initial doses were 10 mg for ROS, ATO and SIM, 20 mg for PRA, and 40 mg for FLU. Patients who failed to reach the target cholesterol level with the initial dosage where titrated to the next highest dosage (20 and 40 mg for ROS and PRA, 20, 40 and 80 mg for ATO and SIM, and 40 and 80 mg for FLU). Type of intervention Primary prevention. Economic study type Cost-utility analysis. Study population The study

NHS Economic Evaluation Database.2006

53. Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people

Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people Mihaylova B, Briggs A, Armitage J, Parish S, Gray A, Collins R Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Simvastatin 40 mg/day was compared with placebo for an average of 5 years. Different age groups with differing risks of vascular disease were evaluated in the primary analysis. The average 5-year risk of vascular events

NHS Economic Evaluation Database.2006

54. Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people.

Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people. 17098764 2006 12 01 2006 12 11 2014 09 07 1756-1833 333 7579 2006 Dec 02 BMJ (Clinical research ed.) BMJ Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people. 1145 To evaluate the cost effectiveness of 40 mg simvastatin daily continued for life in people of different ages (...) with differing risks of vascular disease. A model developed from a randomised trial was used to estimate lifetime risks of vascular events and costs of treatment and hospital admissions in the United Kingdom. 69 hospitals in the UK. 20,536 men and women (aged 40-80) with coronary disease, other occlusive arterial disease, or diabetes. 40 mg simvastatin daily versus placebo for an average of 5 years. Cost effectiveness of 40 mg simvastatin daily expressed as additional cost per life year gained. Major

BMJ2006 Full Text: Link to full Text with Trip Pro

55. Cholesterol lowering with simvastatin reduced stroke in patients with, or at risk of, vascular disease

Cholesterol lowering with simvastatin reduced stroke in patients with, or at risk of, vascular disease Cholesterol lowering with simvastatin reduced stroke in patients with, or at risk of, vascular disease | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Cholesterol lowering with simvastatin reduced stroke in patients with, or at risk of, vascular disease Article Text Therapeutics Cholesterol lowering with simvastatin reduced stroke in patients with, or at risk of, vascular disease Free S Claiborne Johnston , MD, PhD Statistics from Altmetric.com

Evidence-Based Medicine (Requires free registration)2005

56. Cholesterol lowering with simvastatin reduced stroke in patients with, or at risk of, vascular disease

Cholesterol lowering with simvastatin reduced stroke in patients with, or at risk of, vascular disease Cholesterol lowering with simvastatin reduced stroke in patients with, or at risk of, vascular disease | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Cholesterol lowering with simvastatin reduced stroke in patients with, or at risk of, vascular disease Article Text Treatment Cholesterol lowering with simvastatin reduced stroke in patients with, or at risk of, vascular disease Free Sandra Ireland

Evidence-Based Nursing (Requires free registration)2005

57. Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals.

Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals. 15910950 2005 05 24 2005 09 06 2016 11 24 1474-547X 365 9473 2005 May 21-27 Lancet (London, England) Lancet Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals. 1779-85 Statin therapy reduces the rates of heart attack, stroke, and (...) revascularisation among a wide range of individuals. Reliable assessment of its cost-effectiveness in different circumstances is needed. 20,536 adults (aged 40-80 years) with vascular disease or diabetes were randomly allocated 40 mg simvastatin daily (10,269) or placebo (10,267) for an average of 5 years. Comparisons were made of hospitalisation and statin costs (2001 UK prices) during the scheduled treatment period between all simvastatin-allocated versus all placebo-allocated participants. Cost-effectiveness

Lancet2005

58. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial

Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin (...) , pravastatin and simvastatin: analysis of the STELLAR trial Hirsch M, O'Donnell J C, Jones P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of rosuvastatin (10 - 40 mg/day), atorvastatin (10 - 80 mg/day), pravastatin (10 - 40 mg

NHS Economic Evaluation Database.2005

59. Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20536 individuals

Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20536 individuals Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20536 individuals Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20536 individuals Heart Protection Study Collaborative Group (...) Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of simvastatin (40 mg/day) for the reduction of cardiovascular events was examined. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis

NHS Economic Evaluation Database.2005

60. Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial)

Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial) Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial) Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared (...) with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial) Miller P S, Smith D G, Jones P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use rosuvastatin (10, 20 or 40 mg) in the treatment of patients

NHS Economic Evaluation Database.2005